Kidney Care Articles & Analysis
21 news found
Having randomized more than 13,000 patients with CKD and T2D around the world, the Phase III program with finerenone in CKD and T2D comprises two completed and published studies, evaluating the effect of finerenone versus placebo on top of standard of care on both renal and cardiovascular outcomes. FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease ...
ByBayer AG
Having randomized more than 13,000 patients with CKD and T2D around the world, the Phase III program with finerenone in CKD and T2D comprises two completed and published studies, evaluating the effect of finerenone versus placebo on top of standard of care on both renal and cardiovascular outcomes. FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease ...
ByBayer AG
Quanta Dialysis Technologies Inc (“Quanta or “The Company”), a medical technology company committed to making kidney care more accessible with its SC+ hemodialysis system, announced today that CEO John E. ...
Having randomized more than 13,000 patients with CKD and T2D around the world, the Phase III program with finerenone in CKD and T2D comprises two completed and published studies, evaluating the effect of finerenone versus placebo on top of standard of care on both renal and cardiovascular outcomes. FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease ...
ByBayer AG
Having randomized more than 13,000 patients with CKD and T2D around the world, the Phase III program with finerenone in CKD and T2D comprises two completed and published studies, evaluating the effect of finerenone versus placebo on top of standard of care on both renal and cardiovascular outcomes. FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease ...
ByBayer AG
QUANTA Dialysis Technologies Ltd (“QUANTA” or the “Company”), a medical technology company committed to making kidney care more accessible with its SC+ haemodialysis system, has released a new report that suggests people with kidney failure who wish to do home dialysis face unequal access across the UK. The Bridging the ...
The company will evaluate the safety and efficacy of VX-147 in a single pivotal clinical trial designed to assess the impact of VX-147, on top of standard of care, on kidney function and proteinuria in people with AMKD. The primary endpoint of this study is reduction in the rate of decline of kidney function as measured by estimated glomerular ...
Coralville, Iowa and Deerfield, Ill., March 9, 2022 – Digital Diagnostics and Baxter International Inc. announced a long-term strategic partnership to help front line care providers deliver high-quality care and improve care outcomes. The partnership includes plans to offer Digital Diagnostics’ industry-leading IDx-DR® autonomous AI software as a diagnostic service combined with ...
Having randomized more than 13,000 patients with CKD and T2D around the world, the Phase III program with finerenone in CKD and T2D comprises two completed and published studies, evaluating the effect of finerenone versus placebo on top of standard of care on both renal and cardiovascular outcomes. FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease ...
ByBayer AG
A July 2019 White House executive order on kidney care (the Advancing American Kidney Health Initiative) proposed that 80% of new patients with end-stage renal disease (ESRD) be treated with either kidney transplantation or home dialysis by 2025, a significant increase from current rates, which are below 20%. ...
Versius is being used to perform a range of high-volume general surgery and urological procedures, helping to treat patients with colorectal and urological cancers, bowel and kidney disease. High tech surgical care is highly prominent in the health system in Egypt, with adoption of the latest technology for RAS growing rapidly in Ministry of Health supported ...
Combined use of a VEGF tyrosine kinase inhibitor (TKI) and checkpoint inhibitor is already standard of care in advanced kidney, cervical and endometrial cancers. There has been suggestion that such a combination may have clinical activity in some microsatellite stable (MSS) GI malignancies. ...
Having randomized more than 13,000 patients with CKD and T2D around the world, the Phase III program with finerenone in CKD and T2D comprises two completed and published studies, evaluating the effect of finerenone versus placebo on top of standard of care on both renal and cardiovascular outcomes. FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease ...
ByBayer AG
For children and adolescents with chronic kidney disease (CKD), as for adults, the unmet need is high for new treatments to delay disease progression and preserve kidney function / The Phase III study FIONA will investigate the effect of finerenone in pediatric patients with CKD and severely increased proteinuria Bayer announced today the initiation of the FIONA ...
ByBayer AG
“Consistent with our commitment to patients and providers, we are focused on operating responsibly, sustainably, and transparently as we continue to reinvent a dialysis care delivery model and equipment that hasn’t changed in decades. ...
The effect of finerenone on the composite kidney outcomes was reflected by a 36% relative risk reduction of end-stage kidney disease (ESKD). ...
ByBayer AG
Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”, a medical technology company committed to making kidney care more accessible with its SC+ haemodialysis system), is proud to sponsor a new photography exhibition Survivors: Life Unfiltered, running from 26 October to 7 November 2021, at the OXO Gallery in London. This exhibition ...
Quanta Dialysis Technologies Ltd (“Quanta” of the “Company”, a medical technology company committed to making kidney care more accessible with its SC+ haemodialysis system, announced today the results of the UK Dialysis Patient Experience Survey, showing the wide variance in care experienced by UK dialysis patients, as ...
The ExoTRU test will be the first ever commercially available test capable of discriminating between types of kidney rejection, providing critical information to assist clinician decision making and optimize patient care. ...
She also spent over 10+ years at DaVita leading many innovative projects and holding several key operational roles in kidney care, international and population health. Prior to joining DaVita, Pooja held many operations roles at multiple academic medical centers and began her career at Kaiser Permanente. ...